TRPV2 and glioblastoma: In glioblastoma, TRPV2 is part of an interactome-based signature complex (Doñate-Macián et al., 2018), which is negatively associated with patient survival, and it is expressed in high risk of recurrence and temozolomide-resistant patients (Santoni et al., 2020a).